HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarBacktestsPricing
Theme
Help Login Register
Market News Stocks News ETF News Crypto News

MediWound Ltd.

Contributing Author

Recent Articles by MediWound Ltd.

Nov-05
MediWound to Report Third Quarter 2025 Financial Results MDWD GlobeNewswire
Nov-03
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid MDWD GlobeNewswire
Sep-29
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares MDWD GlobeNewswire
Sep-25
MediWound Expands Global Reach with Marketing Approval of NexoBrid in Australia MDWD GlobeNewswire
Sep-02
MediWound's NexoBrid to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress MDWD GlobeNewswire
Aug-20
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference MDWD GlobeNewswire
Aug-14
MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update MDWD GlobeNewswire
Aug-13
MediWound Announces New EscharEx Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers MDWD GlobeNewswire
Aug-04
MediWound to Report Second Quarter 2025 Financial Results MDWD GlobeNewswire
May-21
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update MDWD GlobeNewswire
May-13
MediWound Announces Publication of Phase II EscharEx Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers MDWD GlobeNewswire
May-05
MediWound to Report First Quarter 2025 Financial Results MDWD GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

Learn more about FINVIZ*Elite